<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047031</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0280</org_study_id>
    <nct_id>NCT03047031</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an active surveillance study to monitor the real world safety of nintedanib in Indian&#xD;
      patients with Idiopathic Pulmonary Fibrosis. The safety of nintedanib has been assessed in&#xD;
      clinical trials.This active surveillance aims to collect the safety data of 200 IPF patients&#xD;
      treated with nintedanib in approved indication after the commercial availability of the drug&#xD;
      in India (23rd January 2017). The objective is to look at safety of nintedanib in the real&#xD;
      world setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all Adverse Drug Reactions (ADRs) in nintedanib treated patients</measure>
    <time_frame>up to 56 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of all serious adverse events (SAEs) in nintedanib treated patients</measure>
    <time_frame>up to 56 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who require dose reductions, interruptions and discontinuation due to adverse events</measure>
    <time_frame>up to 56 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients who started treatment with nintedanib after 23rd January, 2017 and have permanently discontinued the drug (as decided by the investigator) at the time of participation in the active surveillance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients who started treatment with nintedanib after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>Patients who have been newly prescribed nintedanib at the time of participation in the active surveillance</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This active surveillance will include all IPF patients treated with nintedanib per the&#xD;
        inclusion/exclusion criteria at selected centres during the first two years after the&#xD;
        commercial availability of the drug.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with documented diagnosis of Idiopathic Pulmonary Fibrosis (IPF) based upon&#xD;
             ATS/ERS/JRS/ALAT 2011 guidelines (nintedanib na√Øve or pirfenidone pre-treated) who&#xD;
             have initiated or will initiate nintedanib according to the package insert after the&#xD;
             commercial availability of drug in India (23rd January 2017).&#xD;
&#xD;
          -  Patients in whom it is possible to obtain voluntary informed consent either from the&#xD;
             patient or patient's legally authorised representative (applicable for Group B and C&#xD;
             patients).&#xD;
&#xD;
          -  Patients in whom data collection is possible from the medical records (applicable for&#xD;
             Group A and B patients)&#xD;
&#xD;
          -  Further inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who were previously treated with nintedanib.&#xD;
&#xD;
          -  Patients who have initiated or will initiate nintedanib concomitantly with&#xD;
             pirfenidone..&#xD;
&#xD;
          -  Patients who are participating in a clinical trial.&#xD;
&#xD;
          -  Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Johns medical College and Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priya Ramachandra</last_name>
      <phone>9663590386</phone>
      <email>supriarvind@yahoo.co.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gleneagles Global Hospital</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijil Rahulan</last_name>
      <phone>+91-044-44777000</phone>
      <email>vkrahulan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sri Ramakrishna Hospital</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Mohankumar</last_name>
      <phone>919894622018</phone>
      <email>tmkdr@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Artemis Health Institute</name>
      <address>
        <city>Gurgaon</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ASHOK RAJPUT</last_name>
      <phone>911244511111</phone>
      <email>ashok.rajput@artemishospitals.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asthma Bhawan</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virendra Singh</last_name>
      <phone>919414051212</phone>
      <email>drvirendrasingh93@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CK Birla Hospitals, The Calcutta Medical Research Institute</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raja Dhar</last_name>
      <phone>91-033-40904090</phone>
      <email>docaardee@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Allergy Asthma Bronchitis Institute, Kolkata</name>
      <address>
        <city>Kolkatta</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alok Gopal Ghoshal</last_name>
      <phone>91-9830068023</phone>
      <email>agghosal@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King George Medical University</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surya Kant</last_name>
      <phone>+91-5222255167</phone>
      <email>skantpulmed@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midland Healthcare and Research Centre</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhanu Singh</last_name>
      <phone>0522-2333333</phone>
      <email>bps2159@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bhatia Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujeet Rajan</last_name>
      <phone>91-9820191302</phone>
      <email>skrajan@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P.D. Hinduja National Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zarir Udwadia</last_name>
      <phone>22-24447353</phone>
      <email>zfu@hindujahospital.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Getwell Hospital and Research Institute</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Nathuram Swarnakar</last_name>
      <phone>919314249227</phone>
      <email>drrajeshswarnakar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ketki Research Institute of Medical Sciences(KRIMS) Hospital</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashok Arbat</last_name>
      <phone>+91-9822466640</phone>
      <email>ashok_arbat@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metro Multispeciality Hospital</name>
      <address>
        <city>Noida</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepak Talwar</last_name>
      <phone>91-120-2533481</phone>
      <email>dtlung@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grant Medical Foundation, Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahavir Modi</last_name>
      <phone>+91-9822253596</phone>
      <email>drm_modi@yahoo.co.in</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

